Gene therapy trial aims to restore vision in blinding eye disease
NCT ID NCT04278131
Summary
This early-stage trial is testing a new gene therapy called BS01 for people with retinitis pigmentosa, a genetic eye disease that causes vision loss. The main goals are to check if the treatment is safe and to see if it can improve patients' ability to detect light, motion, and objects. The study will enroll about 20 adults with advanced vision loss from this condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
New Jersey Retina
RECRUITINGTeaneck, New Jersey, 07666, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.